menu
    • menu

    Company profile for H. Lundbeck AS

    NEW Drugs in Dev: 49
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    H. Lundbeck ASFlag
    Country
    Country
    --
    Address
    Address
    --
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck drug candidate shows promise in Cushing's disease trial
    Lundbeck drug candidate shows promise in Cushing's disease trial

    15 Jun 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/lundbeck-drug-candidate-shows-promise-cushings-disease-trial-2026-06-14/

    REUTERS
    15 Jun 2026
    Share Share
    Lundbeck to Present Neuroendocrine, Immunology Data at ENDO
    Lundbeck to Present Neuroendocrine, Immunology Data at ENDO

    10 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-to-present-new-patient-data-on-neuroendocrine-and-neuroimmunology-programs-at-endo-2026-302796363.html

    PR NEWSWIRE
    10 Jun 2026
    Share Share
    Lundbeck Presents Positive Phase IIb Data for Bocunebart at AHS
    Lundbeck Presents Positive Phase IIb Data for Bocunebart at AHS

    04 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-presents-positive-phase-iib-data-for-bocunebart-lu-ag09222-anti-pacap-mab-in-migraine-prevention-at-the-ahs-congress-302792072.html

    PR NEWSWIRE
    04 Jun 2026
    Share Share
    Lundbeck Presents VYEPTI and Bocunebart Migraine Data at AHS
    Lundbeck Presents VYEPTI and Bocunebart Migraine Data at AHS

    04 Jun 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260603223857/en/Lundbeck-Presents-New-VYEPTI-eptinezumab-jjmr-and-Bocunebart-Migraine-Data-at-the-American-Headache-Society-68th-Annual-Scientific-Meeting

    BUSINESSWIRE
    04 Jun 2026
    Share Share
    Lundbeck Partner with Cradle to Discover Brain Disorder Therapies
    Lundbeck Partner with Cradle to Discover Brain Disorder Therapies

    03 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-partners-with-cradle-to-discover-and-optimize-brain-disorder-treatments-302789396.html

    PR NEWSWIRE
    03 Jun 2026
    Share Share
    Lundbeck's Vyepti Approved in South Korea for Migraine Prevention
    Lundbeck's Vyepti Approved in South Korea for Migraine Prevention

    26 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-receives-marketing-authorization-for-vyepti-eptinezumab-in-south-korea-for-the-preventive-treatment-of-migraine-302781558.html

    PR NEWSWIRE
    26 May 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search